NanoString and Abcam Expand Collaboration to Advance Spatial Multiomics Research
November 09 2022 - 6:00AM
Business Wire
Inclusion of Abcam validated antibodies in
CosMx curated protein panel provides the first high-plex spatial
multiomic solution at single-cell and subcellular resolution
Data from the CosMx human immuno-oncology
64-plex protein panel will be presented at the 37th Annual Meeting
of the Society of Immunotherapy of Cancer Conference (SITC)
NanoString Technologies, Inc. (NASDAQ: NSTG), a leading provider
of life science tools for discovery and translational research, and
Abcam (AIM: ABC; NASDAQ: ABCM), a global life science company
working together with researchers to advance science and enable
faster breakthroughs, today announced the expansion of their
long-standing relationship with a new agreement to co-market Abcam
antibodies for NanoString’s high-plex spatial multiomic
solutions.
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20221109005126/en/
Under the terms of the agreement, Abcam RabMAb™ recombinant
antibodies will be commercialized as part of the first 64-plex
protein panel for NanoString’s CosMx™ Spatial Molecular Imager
(SMI). Jointly developed and validated by NanoString and Abcam, the
human immuno-oncology panel is the first on the market to combine
high-plex spatial proteomic and transcriptomic analyses at
single-cell and subcellular resolution. This provides unprecedented
insights into immune cells, tumors and their neighborhood and aims
to accelerate immune-oncology research supporting a better
understanding of clinical response and therapeutic resistance.
“We have partnered with Abcam to facilitate access to their
broad portfolio of high-quality, validated antibodies to augment
our CosMx protein panels,” said Brad Gray, president and CEO of
NanoString. “This relationship will further expand the depth and
breadth of spatial biology offerings on NanoString instrumentation
into new frontiers of human biology down to single-cell resolution—
a true revolution in the spatial biology field.”
“We are excited to enter a new phase of our relationship with
NanoString. For the past six years, our teams have worked together
to accelerate the development of novel technologies for the
biomarker and clinical research community,” said John Baker, SVP of
Marketing of Abcam. “We are hopeful that these innovations will
unlock the full potential of spatial biology and will ultimately
help improve care for people with cancer.”
NanoString will host a symposium at the 37th Annual Meeting of
the Society of Immunotherapy of Cancer Conference (SITC) on Nov. 10
from 11:40 AM to 1:10 PM EST and will highlight the CosMx protein
capability co-developed with Abcam. In the coming months,
NanoString and Abcam will co-host webinars and events to share
insight on spatial biology in immuno-oncology and other
applications such as neuroscience.
About NanoString’s CosMx Spatial Molecular Imager:
The CosMx™ SMI is the newest product in NanoString’s
industry-leading spatial analysis tools portfolio, joining the
GeoMx® Digital Spatial Profiler (DSP). The CosMx SMI extends
spatial research to single cell and subcellular resolution across
the entire tissue section. The platform currently enables imaging
and quantification of 1,000 RNA and 64 protein targets in
Formalin-Fixed Paraffin Embedded (FFPE) and fresh frozen tissue.
The commercial CosMx SMI instruments are expected to ship later
this year. In the meantime, researchers can apply the power of SMI
to their tissue samples through the SMI Technology Access Program
service provided by NanoString. For more information, email
smitap@nanostring.com. To learn more about NanoString's CosMx
Spatial Molecular Imager, visit www.nanostring.com/CosMx.
About NanoString Technologies, Inc.
NanoString Technologies, a leader in spatial biology, offers an
ecosystem of innovative discovery and translational research
solutions, empowering our customers to map the universe of biology.
The GeoMx® Digital Spatial Profiler, cited in more than 160
peer-reviewed publications, is a flexible and consistent solution
combining the power of whole tissue imaging with gene expression
and protein data for spatial whole transcriptomics and proteomics
from one FFPE slide. The CosMx™ Spatial Molecular Imager (SMI) is
an FFPE-compatible, single-cell imaging platform powered by spatial
multiomics enabling researchers to map single cells in their native
environments to extract deep biological insights and novel
discoveries from one experiment. The AtoMx™ Spatial Informatics
Platform (SIP) is a cloud-based informatics solution with advanced
analytics and global collaboration capabilities, enabling powerful
spatial biology insights anytime, anywhere. The CosMx SMI and AtoMx
SIP platforms are expected to launch in 2022. At the foundation of
our research tools is our nCounter® Analysis System, cited in more
than 6,200 peer-reviewed publications, which offers a secure way to
easily profile the expression of hundreds of genes, proteins,
miRNAs, or copy number variations, simultaneously with high
sensitivity and precision. For more information, visit
www.nanostring.com.
About Abcam
At Abcam, we believe that the scientific community goes further,
faster, when we go there together. And to keep on making
ground-breaking discoveries, we need to work together in new ways.
That’s why we’re constantly innovating to help scientists drive
their research forward by providing products and solutions that
play an essential role in fundamental research, drug discovery,
diagnostic and therapeutic applications.
We started with a simple mission: to provide the best biological
reagents to life scientists worldwide. Today, we help 750,000
researchers in over 130 countries deliver faster breakthroughs in
areas like cancer, neurological disorders, infectious diseases, and
metabolic disorders.
To find out more, visit us at www.abcam.com and corporate.abcam.com.
Forward-Looking Statements
This news release contains forward-looking statements within the
meaning of Section 27A of the Securities Act of 1933 and Section
21E of the Securities Exchange Act of 1934 and the Private
Securities Litigation Reform Act of 1995. These forward-looking
statements include statements regarding NanoString’s products and
the anticipated launch of new products and technology. Such
statements are based on current assumptions that involve risks and
uncertainties that could cause actual outcomes and results to
differ materially. These risks and uncertainties, many of which are
beyond NanoString’s control, include market acceptance of
NanoString’s products; adverse conditions in the general domestic
and global economic markets; the effects of ongoing litigation; the
impact of competition; the impact of expanded sales, marketing, and
product development on operating expenses; delays or other
unforeseen problems with respect to manufacturing and product
development; as well as the other risks set forth in NanoString’s
filings with the Securities and Exchange Commission. These
forward-looking statements speak only as of the date hereof.
NanoString disclaims any obligation to update these forward-looking
statements.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20221109005126/en/
Doug Farrell, NanoString Vice President, Investor Relations
& Corporate Communications dfarrell@nanostring.com Phone:
206-602-1768 Pierre Peotta and Alex Bannister
external.comms@abcam.com
Abcam (NASDAQ:ABCM)
Historical Stock Chart
From Aug 2024 to Sep 2024
Abcam (NASDAQ:ABCM)
Historical Stock Chart
From Sep 2023 to Sep 2024